ASH 2021 infographic summarising the abstract focused on an updated summary of thrombotic events and thrombotic microangiopathies in people with haemophilia A receiving emicizumab▼ prophylaxis

As of May 2021, **emicizumab** has been used by **>11,400 patients** across the world[1,*]

Emicizumab is approved for routine prophylaxis in people with congenital haemophilia A (PwcHA) with/without FVIII inhibitors in >100 and >90 countries, respectively

No new TMAs or TEs associated with aPCC use have been reported since the last safety update[1,2]

37 **TEs not associated with concomitant aPCC use** were identified in this safety report (May 2021)[1]

30 non-aPCC-related TEs were **not associated with CVADs**[1]

7 non-aPCC-related TEs were **associated with CVADs**[1]

In **6 of the 30 non-CVAD-associated** cases, the event led to the discontinuation of emicizumab[1]

Of the CVAD-related events,

4 were reported as recovering/resolving[1]



No changes were made to emicizumab prophylaxis in ~50% of patients who experienced a TE[1,†]

- Dose not changed
- Drug withdrawn
- Dose modified
- Status unknown

91.9%

34 of the 37 non-aPCC-related TEs were associated with **≥1 CV risk factor or other risk factors for thrombosis**[1]



At time of analysis, the majority of TEs were recovered or resolving[1]

- Recovered/resolving
- Not recovered/resolving‡
- Not reported
- Status unknown

TEs and TMAs **without concomitant aPCC** were not identified as a safety risk for PwcHA receiving emicizumab prophylaxis[1]

▼Emicizumab is subject to additional monitoring. This will allow quick identification of new safety information. We encourage patients and caregivers to report any adverse reactions to their healthcare professional.
*Data cut-off 15 May 2021. †Excluding four TEs with fatal outcome. ‡Includes four TEs with fatal outcome.
aPCC, activated prothrombin complex concentrate; CV, cardiovascular; CVAD, central venous access device; FVIII, factor VIII; PwcHA, people with congenital haemophilia A; TE, thrombotic event; TMA, thrombotic microangiopathy

1. Howard M, et al. *Blood* 2021; poster presentation at ASH 2021; 2. Lee L, et al. *Haemophilia* 2020;26:P131; oral presentation at EAHAD 2020

M-XX-00007587
Date of preparation: November 2021